Q3 2024 report

Strong growth and significant pipeline momentum

Conference call for investors and analysts

24 October 2024

Forward-looking statements

This presentation contains certain forward-looking statements with respect to certain of the Company's current expectations and projections about future events. These statements, which sometimes use words such as "intend," "proposed," "plan," "expect," and words of similar meaning, reflect management's beliefs and expectations and involve a number of risks, uncertainties and assumptions that could cause actual results and performance to differ materially from any expected future results or performance expressed or implied by the forward-looking statement. Statements contained in this presentation regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. The information contained in this presentation is subject to change without notice and, except as required by applicable law, the Company does not assume any responsibility or obligation to update publicly or review any of the forward-looking statements contained in it. You should not place undue reliance on forward-looking statements, which speak only as at the date of this presentation.

Agenda

Business update		Guido Oelkers, Chief Executive Officer
Financials		Henrik Stenqvist, Chief Financial Officer
R&D Pipeline		Lydia Abad-Franch, Head of R&D and Chief Medical Officer
Summary and Q&A		

Demand growth in strategic portfolio in Q3 2024

Positive progress in clinical development milestones

High double-digit performance at CER

Revenue Q3 - SEK 6,894 M, +39% (excluding RSV revenue grew 16%)
Adjusted EBITA margin 43%

Strategic portfolio[1] grew 113% in Q3

- Beyfortus® royalties SEK 1,478 M
- Doptelet®* SEK 1,039 M, +65%
- Vonjo® SEK 379 M, +13%
- Altuvoct® SEK 129 M
- Aspaveli®/Empaveli® SEK 270 M, +66%
- Altuviiio® royalties SEK 152 M

Key milestones for late-stage pipeline unlocking growth potential

- Altuvoct: Strong uptake and launch in Germany

ALTUVOCT®
efanesoctocog alfa (recombinant coagulation factor VIII, Fc-Von Willebrand Factor-XTEN Fusion Protein)

- Aspaveli: Positive topline Phase 3 VALIANT (C3G, primary IC-MPGN)
- Doptelet: ITP - Japan submission. US paediatric submission
- Gamifant: 1000th patient treated. sHLH fast track filing before end of year.

2024 outlook - Updated

Revenue: anticipated to grow by a mid-teens percentage at CER (previously low double-digit)
Adjusted EBITA margin: anticipated to be in the mid-30s per cent of revenue (unchanged)

Sobi Strategy

- **Lead in Haematology**
- **Capture the value of the pipeline**
- **Grow Immunology**
- **Go Global**

Per cent growth calculated in CER

1: Strategic portfolio includes Altuvoct, Aspaveli/Empaveli, Doptelet, Gamifant, Vonjo and Zynlonta and royalties from Beyfortus and Altuviiio. * including a milestone payment after approval in China of SEK 53M

Robust growth across business areas and regions

*YTD growth **24%** driven by new approvals and momentum of launches*

Revenue by segment

	Q3 2024 SEK M	change %	ratio %
Haematology	4,000	+18	58
– Haemophilia	*2,283*	*+1*	*33*
Immunology	2,583	+96	37.5
Specialty Care	311	+13	4.5
Total	**6,894**	**+39**	**100**

Revenue by region

	Q3 2024 SEK M	change %	ratio %
Europe	2,319	+14	33
North America	1,969	+15	29
International	668	+9	10
Other	1,938	>200	28
Beyfortus royalty	*1,478*	*>200*	
Altuviiio royalty	*152*	*>200*	
Total	**6,894**	**+39**	**100**

Revenue at actual exchange rates; change at constant exchange rates (by segment and geographic area). International region previously called rest of the world.
Other refers to royalty revenue.

Strategic portfolio – 56% of revenue in Q3

SEK M	Q3 2024	Q3 2023	Change at CER	Jan-Sep 2024
Altuvoct	129	n/a	n/a	134
Aspaveli/Empaveli	270	169	66%	760
Doptelet*	987	650	57%	2,671
Gamifant	405	438	-3%	1,365
Vonjo	379	347	13%	1,046
Zynlonta	29	15	96%	68
Altuviiio royalty	152	42	>200%	400
Beyfortus royalty	1,478	263	>200%	1,803
Strategic portfolio	3,830	1,924	113%	8,247

Total revenue Q3



Graphics are representative

*excluding milestone payment received after approval in China

Growth portfolio and pipeline progression



YTD: year to date. sHLS/MAS: secondary haemophagocytic lymphohistiocytosis /macrophage activating syndrome. C3G and IC-MPGN: Complement 3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis. CRG: chronic refractory gout. Altuvoct is marketed by Sanofi in the US under the brand name Altuviiio. * Pipeline products subject to regulatory approvals.

Altuvoct already showing rapid adoption in Germany

Sobi Haemophilia A market share increasing by more than 6%



- Achieving highly sustained FVIII levels in the non-haemophilia range (above 40%) for the majority of the week with a once weekly injection
- Evidence supported by two NEJM publications for XTEND-1 and XTEND-KIDS pivotal studies

Altuvoct Launch

- Rapid patient adoption in Germany with sales of SEK 129 M
  - Patients coming from Elocta and competitive treatments (including non-factor products)
- Sobi Market Share (Elocta +Altuvoct) in Haemophilia A increased by >6% points in Germany within 2.5 months of launch
- The product offers high levels of protection with its sustained effectiveness in the non-haemophilia FVIII range, while also reducing the treatment burden.

ALTUVOCT™
efanesoctocog alfa (recombinant coagulation factor VIII, Fc-Von Willebrand Factor-XTEN Fusion Protein)

Sales in SEK M at actual exchange rates; change at constant exchange rates.

Aspaveli PNH & Nephrology - Positive Phase 3 results in rare kidney diseases

ASPAVELI (pegcetacoplan)

Solid Aspaveli/Empaveli
SEK 270 M
+66% Q3



PNH

- Continued strong growth momentum across EU, International and Canada as more patients switch to Aspaveli / Empaveli seeking improved control of their PNH
- Q3 SEK 270 M (+66% at CER). YTD revenue increased by 91%

Nephrology

- Positive topline results from Phase 3 VALIANT study in C3G and primary IC-MPGN
  - Primary Endpoint met 68% ($p<0.0001$) reduction in proteinuria in broad population
  - Statistically significant results in all patient subgroups
- Full data to be presented at ASN Saturday, October 26, 11:00 PDT Oral Abstract Session, High impact clinical trials (*Sobi IR call Tuesday, October 29th*)
- Estimated 8,000 diagnosed patients in Europe with currently no approved targeted therapy
- VALIANT data to be submitted in EU and Japan for approval in early 2025

enFuse injector in collaboration with Enable Injections has the potential to improve patients' self-administration experience with minimal disruption to their daily lives.

Sales in SEK M at actual exchange rates; change at constant exchange rates. ODD: orphan drug designation.

Sobi's view on pegcetacoplan in C3G – IC-MPGN

#1 We are confident in pegcetacoplan's blockbuster potential

We remain confident in a diagnosed patient population of at least 8k patients with C3G or IC-MPGN in Europe
Additional potential opportunity in Japan and selected international markets

#2 Increasing opportunity – today's numbers are more a reflection of today's options

Unlocking the potential requires understanding the individual complete patient journey

#3 The data support pegcetacoplan's use in a number of patient subgroups

Pegcetacoplan is the only investigational product with Phase 3 results in C3G and IC-MPGN including adolescent and adult patients, as well as pre and post transplant patients

#4 Pegcetacoplan shown to reduce proteinuria by 68%

The Spanish Group for the Study of Glomerular Diseases (GLOSEN) establish 50% as the threshold for being clinically meaningful – and pegcetacoplan is the only product that clearly surpasses that threshold

Doptelet continues to show strong momentum across all regions

Doptelet
SEK 1,039 M
+65% Q3



- Continued strong momentum in the business driven by increase market share gains in all regions
- Doptelet delivers a favorable product profile with proven efficacy, convivence and favorable tolerability
- Milestone revenue in the quarter from the partner in China of SEK 53 M following the approval of Doptelet for ITP in China

Sales in SEK M at actual exchange rates; change at constant exchange rates.

Vonjo showing continued growth momentum

Vonjo
SEK 379 M
+13% Q3



- 12% quarter on quarter growth (13% YoY)
- Field activity level significantly increased
- Product awareness increased to >70%[1]
- Our long-term growth strategy is to tap into the potential related to:
  - New indications
  - International markets
  - Myelofibrosis treatment in line with NCCN guidelines*

VONJO® (pacritinib) capsules

Sales in SEK M at actual exchange rates; change at constant exchange rates.
1. Brandimpact data Q3 2024

*In addition to being the preferred option in its indicated population of intermediate and high-risk MF patients with a platelet count <50K, the updated NCCN guidelines recommend the use of pacritinib as a potential treatment option in patients with myelofibrosis associated anemia

Elocta & Alprolix :Continued patient growth and geographical expansion

Elocta
SEK 1,119 M
-9% Q3



Elocta

- Sales impacted by order phasing in International and Altuvoct launch in Germany

Alprolix

- Growth in number of patients, geographic expansion
- Partly offset by continued price pressure in many regions and order phasing in the middle East

Alprolix
SEK 575 M
+8% Q3



Sales in SEK million at actual exchange rates; change at constant exchange rates.

Gamifant set to complete filing in sHLH/MAS by year-end
Kineret: Continued solid growth, + 21% in Q3

Gamifant
SEK 405 M
-3% Q3



Gamifant

- 1,000th patient treated
- Positive patient volumes
- Q3 impacted by destocking / variation in patient treatment

Kineret

- Growth in all regions
- Increased interest in the IL-1 mechanism in inflammation



Kineret
SEK 699 M
+21% Q3



Sales in SEK M at actual exchange rates; change at constant exchange rates.

Agenda

Business update		Guido Oelkers, Chief Executive Officer
Financials		Henrik Stenqvist, Chief Financial Officer
R&D Pipeline		Lydia Abad-Franch, Head of R&D and Chief Medical Officer
Summary and Q&A		

Q3 2024 Revenue and profit & loss

Total revenue (SEK M)



Absolute amounts in SEK million (except EPS) and at actual exchange rates; change at actual exchange rates (statutory view).

Amounts in SEK M	Q3 2024	Q3 2023	Change	Full-year 2023
Total revenue	**6,894**	5,168	33%	**22,123**
Adjusted Gross profit [1,2]	**5,604**	4,033	39%	**17,162**
Adjusted Gross margin [1,2]	**81%**	78%		**78%**
EBITA[1]	**2,923**	1,443	103%	**7,075**
Adjusted EBITA [1,2]	**2,965**	1,545	92%	**7,494**
EBITA margin[1]	**42%**	28%		**32%**
Adjusted EBITA margin [1,2]	**43%**	30%		**34%**
Profit for the period	**1,464**	94	1457%	**2,409**
EPS, before dilution, SEK[3]	**4.27**	0.30	1323%	**7.47**
Adjusted EPS, before dilution, SEK [1,2,3]	**4.36**	0.54	707%	**8.55**
Operating cash flow	**1,201**	1,058	14%	**4,470**
Net debt	**16,880**	20,077		**19,265**

1. Alternative performance measures (APM), see the report for further information
2. Items affecting comparability (IAC), see the report for further information

Outlook 2024
Updated

Revenue

Anticipated to grow by a mid-teen percentage at CER[1]

Adjusted EBITA margin

Anticipated to be in the mid-30s percentage of revenue

1. Constant exchange rates.

Agenda

Business update		Guido Oelkers, Chief Executive Officer
Financials		Henrik Stenqvist, Chief Financial Officer
R&D Pipeline		Lydia Abad-Franch, Head of R&D and Chief Medical Officer
Summary and Q&A		

Solid pipeline progress

Altuvoct

Haemophilia

NEJM XTEND-kids

SEL-212

Chronic Refractory Gout

FDA filing on track

Aspaveli/Empaveli

C3G and IC-MPGN

Positive VALIANT Phase 3 data

enFuse® injector

Collaboration with Enable Injections, Inc.

Doptelet

ITP

Paediatric filing in US

Filing in Japan

C3G and IC-MPGN: Complement 3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis
ITP: immune thrombocytopenia
enFuse® is a trademark of Enable Injections, Inc.

Pegcetacoplan: Positive VALIANT Phase 3 study

Statistically significant reduction in proteinuria in a broad study population

68% (p<0.0001) relative reduction in proteinuria vs placebo at Week 26



- Positive effects consistent across subgroups
  - C3G and IC-MPGN
  - Adolescent and adult
  - Native kidney and transplant
- Secondary endpoints all favor pegcetacoplan treatment
- Favorable safety and tolerability, consistent with established profile
- Full data to be presented at ASN Saturday, October 26, 11:00 PDT Oral Abstract Session, High impact clinical trials (*Sobi IR call Tuesday, October 29th*)

Pegcetacoplan: Device partnership with Enable Injections, Inc.

- enFuse® Injector for subcutaneous delivery of pegcetacoplan
- Goals: enhance patient experience, support adherence, expand choice
- International development and distribution agreement across Sobi territories
- Aim to be available in Europe for PNH, C3G and IC-MPGN

Empaveli Injector® commercialized by Apellis Pharmaceuticals, Inc. in the US

Emapalumab research collaboration on CAR-T toxicities

Hyperinflammation is a common side effect of CAR-T therapy[2,4,10]



Emapalumab could help mitigate CAR-T side effects

Interferon gamma has been shown to play a key role in CRS and ICANS[7-9]

Preclinical evidence suggest that blocking IFNγ could prevent CRS and ICANS without hindering efficacy[8,9]

Proof of concept study underway

Emapalumab Prevention of CAR-T Cell Associated Toxicities Multi-center, open label study (NCT06550141)

Research collaboration with Mass. General Hospital
Harvard Medical School and the Cellular Immunotherapy Program at Massachusetts General Hospital
- Marcela V. Maus, MD, PhD (Sponsor)
- Matthew J. Frigault, MD (Principal Investigator)

Figure adapted from Morris EC, et al. 2022[2] and Baumeister SH, et al. 2022.[4] CAR T: chimeric antigen receptor T cell; CRS: cytokine release syndrome; ICANS: immune effector cell-associated neurotoxicity syndrome. 1. Hayden PJ, et al. *Ann Oncol* 2022;33:259–275; 2. Morris EC, et al. *Nat Rev Immunol* 2022;22:85–96; 3. Gust J, et al. *Front Immunol* 2020;11:577027; 4. Baumeister SH, et al. *Front Oncol* 2022;12:841117; 5. Shaikh S, Shaikh H. CART Cell Therapy Toxicity. 2023. In: StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL):2024; 6. Garcia Borrega J, et al. *Hemasphere* 2019;3:e191; 7: Manni, S., Del Bufalo, F., Merli, P. et al.: Neutralizing IFNγ improves safety without compromising efficacy of CAR-T cell therapy in B-cell malignancies. Nat Commun 14, 3423 (2023). https://doi.org/10.1038/s41467-023-38723-y; 8.Bailey S et al., Blocking IFNγ in CAR-T Reduces Checkpoint Inhibitors and Cell-Mediated Toxicity without Compromising Therapeutic Efficacy in CD19 +malignancies, Blood, 2021; 9: Bailey, S., Vatsa, S., et al.: Blockade or Deletion of IFNγ Reduces Macrophage Activation without Compromising CAR T-cell Function in Hematologic Malignancies. Blood Cancer Discov (2022) 3 (2): 136–153. https://doi.org/10.1158/2643-3230.BCD-21-0181; 10: Schmidt A. et al., Toward Better Understanding and Management of CAR-T Cell–Associated Toxicity. *Annual Rev of Medicine*, 2020

Pacritinib's potential beyond myelofibrosis

Emerging areas of interest

	Characteristics	Current treatment options	Rationale for pacritinib	Sobi supported ISS
VEXAS Vacuoles E1 Ub activating enzyme X-linked Auto-inflammatory disease with Somatic mutations	First described in 2020 Caused by UBA1 gene mutation **Wide range of inflammatory symptoms** affecting multiple organs **Prevalence:** ~1 in 4000 men over age 50[1]	**No standard treatment or approved therapies** JAK inhibition offers some efficacy but, may not target root inflammatory pathways or address cytopenias	Pacritinib's unique kinome profile may further **target additional pathways beyond JAK inhibitors**	**Pacritinib in Vacuoles, E1 Ubiquitin-activating Enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome** (NCT06538181) Principal Investigator: Meagan A Jacoby, M.D., Washington University School of Medicine
CMML Chronic Myelomonocytic Leukemia	Haematopoietic stem cell disorder with features of both **myelodysplastic syndromes and myeloproliferative neoplasms**[1] **Cytopenias and organomegaly** are common **Median survival ~20-40 months**[1] **Prevalence:** ~4 in 100,000 persons[2]	Only curative treatment is **allogeneic haematopoietic stem-cell transplantation (HSCT)**[2]	**Pre-clinical and clinical data**[3-7] indicate a potential benefit of JAK inhibitors Pacritinib's unique kinome profile could be beneficial	**Pacritinib in combination with azacitidine in patients with CMML** (NCT06159491) Principal Investigator: Douglas Tremblay, M.D., Icahn School of Medicine

VEXAS: UBA1, Ubiquitin-associated protein 1; NIAMS, National Institute of Arthritis and Musculoskeletal and Skin; Beck, D. et al. JAMA 2023 Jan 24;329(4):318-324. doi: 10.1001/jama.2022.24836. Based on retrospective data from 163,096 participants in a US community health initiative. NIH, MedlinePlus.gov, literature, press search; Uchino et al. Int J Hematol. 2022;116:463–464.

CMML: 1: SEER Hematopoietic and Lymphoid Neoplasm Database (cancer.gov). 2: Patnaik MM, Tefferi A. *Am J Hematol*. 2024; 99(6): 1142-1165. doi:10.1002/ajh.27271. 3: Hercus et al., Blood, 2009. 4: Padron et al., Blood, 2013. 5: Obba et al., Autophagy, 2015. 6: Wei et al., Blood, 2018. 7: Santini et al.,PLoS One, 2011. 9: Image originally published in ASH Image Bank. Elizabeth L. Courville, MD. ASH Image Bank. 2015; image 60170. © the American Society of Hematology.

Altuvoct: Building further evidence

XTEND-Kids[1]



of patients **had <u>zero</u> bleeding episodes** (47/74)



of patients **had <u>zero</u> joint bleeds** (61/74)



of patients **had <u>zero</u> spontaneous bleeds** (65/74)

Focus on joint health and physical activity



Just one bleed can trigger a vicious cycle of repeat bleeding which leads to arthropathy[2]

FREEDOM Phase 3b study (NCT05817812)

Monitor joint health

Track physical activity

Observe long-term outcomes

1: Malec, L., et al.: Efanesoctocog Alfa Prophylaxis for Children with Severe Hemophilia A. N Engl J Med 2024;391:235-246. DOI: 10.1056/NEJMoa2312611
2. Gringeri A, et al. Haemophilia. 2014. **3.** Single-centre analysis of 203 joints from 66 people with haemophilia A of mixed disease severities: De la Corte-Rodriguez, et al. Haemophilia 2022. **4.** Srivastava A, et al. Haemophilia 2020.

Significant events in 2024

Anticipated major pipeline news flow

Altuvoct **EU approval** ✓

SEL-212 **FDA filing ongoing** ✓

Aspaveli **VALIANT data** ✓

Gamifant **FDA filing**

2024 H1

Altuvoct– Haemophilia A:
- ● Regulatory approval in EU

Doptelet – ITP:
- ● Regulatory approval in China

SEL-212 – Chronic Refractory Gout:
- ● Regulatory submission in the US initiated

2024 H2

Doptelet – ITP:
- ● Regulatory submission in Japan
- ● Paediatric submission in US
- ○ Paediatric submission in EU

Aspaveli/Empaveli – C3G & IC-MPGN:
- ● VALIANT Phase 3 study data readout

Gamifant – sHLH / MAS in rheumatological diseases:
- ○ Regulatory submission in the US (Still's disease cohort)

ITP: immune thrombocytopenia. C3G and IC-MPGN: Complement 3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis. sHLH / MAS: secondary hemophagocytic lymphohistiocytosis / macrophage activation syndrome in patients with underlying rheumatological diseases, specifically Still´s disease and systemic lupus erythematosus.

Continued R&D momentum in 2025

Anticipated major pipeline news flow

2025

Altuvoct – Haemophilia A	• FREEDOM (Phase 3b) initial study data	
Aspaveli / Empaveli – Nephrology	• EU submission • Japan submission	
Gamifant[1] – sHLH / MAS	• US decision • Japan submission	
SEL-212 – Chronic refractory gout	• US decision	
Kineret – Still's disease	• Japan submission	

1. EU submission strategy to be announced in 2025
C3G and IC-MPGN: Complement 3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis.
sHLH / MAS: secondary hemophagocytic lymphohistiocytosis / macrophage activation syndrome in patients with underlying rheumatological diseases, specifically Still´s disease and systemic lupus erythematosus; DLBCL: Diffuse large B-cell lymphoma.

Agenda

Business update		Guido Oelkers, Chief Executive Officer
Financials		Henrik Stenqvist, Chief Financial Officer
R&D Pipeline		Lydia Abad-Franch, Head of R&D and Chief Medical Officer

Summary and Q&A

Summary: Growth and pipeline progress

% growth at CER

Significant growth	Revenue Q3 - SEK 6,894 M, +39% *Strong Beyfortus royalty contribution, excluding RSV portfolio grew 16%*
Strategic portfolio contributing significantly	Doptelet* SEK 1,039 M, +65% Aspaveli/Empaveli SEK 270 M, +66% Vonjo SEK 379 M, +13% Altuviiio royalties SEK 152 M, >200% Beyfortus royalties SEK 1,478 M, >200%
Key milestones in Q3	Altuvoct: Strong first launch in Europe in Germany: XTEND-Kids published in NEJM Aspaveli: VALIANT positive data in C3G and IC-MPGN: enFuse injector collaboration signed with Enable Injections Doptelet filing in Japan for ITP and paediatric indication in the US
2024 Outlook **Updated**	**Revenue:** anticipated to grow by a mid-teens percentage at CER **Adjusted EBITA margin:** anticipated to be in the mid-30s per cent of revenue

Second consecutive year as member of DJSI Europe

Selected as a member of the S&P Yearbook

* including a milestone payment after approval in China of SEK 53M

Q&A

Current development pipeline

Major ongoing clinical studies and medicines in registration in a major region or country



Pipeline news flow

2024 Q4

Gamifant – sHLH / MAS in rheumatological diseases
- Regulatory submission in the US

(Still's disease cohort)

Doptelet – ITP
- Paediatric submission in the EU

2025

Altuvoct – Haemophilia A
- FREEDOM (Phase 3b) initial data

Aspaveli / Empaveli – Nephrology
- EU submission
- Japan submission

Gamifant – sHLH / MAS
- US decision
- Japan filing

SEL-212 – Chronic refractory gout
- US decision

Kineret – Still's disease
- Japan submission

ITP: immune thrombocytopenia.
C3G and IC-MPGN: C3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis.
sHLH / MAS: secondary hemophagocytic lymphohistiocytosis / macrophage activation syndrome in patients with underlying rheumatological diseases, specifically Still´s disease and systemic lupus erythematosus.
CAPS: cryopyrin-associated periodic syndromes.
CRG: chronic refractory gout.

Appendix: Q3 2024 sustainability performance

Highlights in Q3 2024

- **Milestones toward increased access**
  - Publication in NEJM* of full results from Phase 3 XTEND-Kids study (efanesoctogog alfa)
  - Announcement of positive topline results from Phase 3 VALIANT study (pegcetacoplan) together with Sanofi.
- **Awareness and patient support**
  - Shared knowledge at 31st Paediatric Rheumatology Congress, PreS 2024.
  - Raised public awareness during ITP Awareness month and trained employees on Still's Disease Awareness Day.

*NEJM – New England Journal of Medicine

Maintain commitment to patients

- Access to treatment
- Patient centricity and engagement
- Patient and product safety
- Ethical marketing and sales
- Transparent and ethical R&D

Always act responsibly

- An inclusive and diverse workplace that grows people
- Safe, healthy and fair working conditions
- Reduction of environmental footprint
- Responsible sourcing
- Compliance and corruption prevention

Commitment to the UN Global Compact. Contribution to the 2030 Agenda, the UN Sustainable Development Goals and the Paris Agreement

Member of
Dow Jones Sustainability Indices
Powered by the S&P Global CSA

Second consecutive year as member of DJSI Europe

Highlights in Q3 2024

- **Caring for employees**
  - In the wake of Hurricane Helene, Sobi provided assistance to employees affected by the hurricane and supported the overall emergency relief by donating to the American Red Cross.
- **Reducing environmental footprint**
  - In September, Sobi moved into its new global headquarters, a space-, resource- and energy efficient building and office designed to lower Sobi's overall carbon and resource footprint.

Thank you

Swedish Orphan Biovitrum AB (publ)
SE-112 76 Stockholm • Sweden
www.sobi.com